Skip to main content
Fig. 21 | AAPS Open

Fig. 21

From: Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections

Fig. 21

1 L scale up. A Dissolution profile for a 1 L sample of 125 mg/L fresh Yomesan, 0–180 min (black filled symbols), and a 300 µM 20 mL sample (red squares) from Fig. 4A. Dashed lines are the logarithmic fits to both sets of data. B Dissolution profile for both samples 0 to days 2, 4, and 5 at final pHs of 9.33 and 9.17, respectively. C Optical microscope representative images of niclosamide aggregates for the 1 L sample at 60 to 240 min of dissolution-stirring that show very little change in morphology.

Back to article page